Nanotechnology, the science of materials engineered at the 1–100 nanometer (nm) scale, is increasingly applied across domains relevant to elite sport, including equipment engineering, wearable biosensing, nanoparticle-based supplementation, photobiomodulation (PBM) nanotechnology, and quantum dot (QD)-enabled diagnostics; however, the aggregate impact of these applications on measurable athletic performance outcomes remains poorly synthesized. This systematic scoping review, conducted and reported in accordance with PRISMA-ScR, aimed to map and characterize available evidence on nanotechnological applications relevant to athletic and exercise performance across six domains: carbon nanotube (CNT)-reinforced equipment, nano-antioxidant supplementation, nanoparticle-based nutrient delivery, wearable nanosensors, PBM nanotechnology, and QD-based biosensing. A systematic search was performed in PubMed/MEDLINE, Scopus, and Web of Science (inception to 15 June 2026). Eligibility was assessed through four evidence strata: Stratum 1, RCTs and controlled studies in human participants of any training status (direct controlled human evidence; stratum classification determined by study design; population training status recorded as a separate determinant of interpretive generalizability within the stratum); Stratum 2, observational and experimental studies in healthy humans; Stratum 3, validated animal exercise models (restricted a priori to the nano-supplementation domain); and Stratum 4, subdivided into Stratum 4a (systematic reviews, meta-analyses, narrative/comprehensive reviews) and Stratum 4b (materials science studies). Quality appraisal was performed using study-design-specific tools (RoB 2, NOS, SYRCLE, AMSTAR-2, structured narrative frameworks). No formal GRADE certainty-of-evidence assessment was performed. A total of 28 records met inclusion criteria: 12 primary studies across Strata 1–3 and 16 secondary or contextual records in Stratum 4. Direct controlled human evidence (Strata 1–2) was identified for CNT-based insoles, Taopatch® PBM devices, and CNT motion sensors; animal model evidence (Stratum 3) was consistent for nano-antioxidant strategies; and Stratum 4 provided contextual technical and mechanistic framing. No Stratum 1 study applied QDs to elite athletes in vivo. Nanotechnology demonstrates theoretical and emerging translational potential across several domains relevant to athletic and exercise performance; however, direct evidence of meaningful performance enhancement in trained or elite athletes remains very limited. Adequately powered double-blind RCTs in elite athletes, independent nanomaterial characterization, and prospective protocol registration are required before clinical recommendations can be formulated.
No takes yet. Share an insight, caveat, or question.
VITIS et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: